[HTML][HTML] Update on heart failure management and future directions

HM Choi, MS Park, JC Youn - The Korean journal of internal …, 2019 - ncbi.nlm.nih.gov
Heart failure (HF) is an important cardiovascular disease because of its increasing
prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The …

Novel oxidative stress biomarkers with risk prognosis values in heart failure

ML Ng, X Ang, KY Yap, JJ Ng, ECH Goh, BBJ Khoo… - Biomedicines, 2023 - mdpi.com
Oxidative stress (OS) is mediated by reactive oxygen species (ROS), which in
cardiovascular and other disease states, damage DNA, lipids, proteins, other cellular and …

[HTML][HTML] Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics

JR Bhagwan, D Mosqueira, K Chairez-Cantu… - Journal of molecular and …, 2020 - Elsevier
Background Hypertrophic cardiomyopathy (HCM) is a prevalent and complex cardiovascular
condition. Despite being strongly associated with genetic alterations, wide variation of …

Novel therapies for prevention and early treatment of cardiomyopathies: now and in the future

GG Repetti, CN Toepfer, JG Seidman… - Circulation …, 2019 - Am Heart Assoc
Heritable cardiomyopathies are a class of heart diseases caused by variations in a number
of genetic loci. Genetic variants on one allele lead to either a degraded protein, which …

Heart failure with preserved ejection fraction: The pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach

L Stoicescu, D Crişan, C Morgovan, L Avram… - International Journal of …, 2024 - mdpi.com
Heart failure (HF) with preserved ejection fraction (HFpEF) is an increasingly frequent form
and is estimated to be the dominant form of HF. On the other hand, HFpEF is a syndrome …

The future of heart failure with preserved ejection fraction: Deep phenotyping for targeted therapeutics

FR Heinzel, SJ Shah - Herz, 2022 - Springer
Heart failure (HF) with preserved ejection fraction (HFpEF) is a multi-organ, systemic
syndrome that involves multiple cardiac and extracardiac pathophysiologic abnormalities …

[HTML][HTML] Modeling hypertrophic cardiomyopathy: mechanistic insights and pharmacological intervention

D Mosqueira, JGW Smith, JR Bhagwan… - Trends in molecular …, 2019 - cell.com
Hypertrophic cardiomyopathy (HCM) is a prevalent and complex cardiovascular disease
where cardiac dysfunction often associates with mutations in sarcomeric genes. Various …

Myocardial contractility: historical and contemporary considerations

WW Muir, RL Hamlin - Frontiers in Physiology, 2020 - frontiersin.org
The term myocardial contractility is thought to have originated more than 125 years ago and
has remained and enigma ever since. Although the term is frequently used in textbooks …

[HTML][HTML] Omecamtiv mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management

PH Patel, M Nguyen, R Rodriguez, S Surani, G Udeani - Cureus, 2021 - ncbi.nlm.nih.gov
Heart failure (HF) is a major public health problem in the United States as well as worldwide.
Chronic heart failure is a syndrome of reduced cardiac output resulting from impaired …

New targets in heart failure drug therapy

M Correale, L Tricarico, M Fortunato… - Frontiers in …, 2021 - frontiersin.org
Despite recent advances in chronic heart failure management (either pharmacological or
non-pharmacological), the prognosis of heart failure (HF) patients remains poor. This poor …